Urinary Proteome Analysis Enables Assessment of Renoprotective Treatment in Type 2 Diabetic Patients with Microalbuminuria

Sten Andersen; Harald Mischak; Petra Zürbig; Hans-Henrik Parving; Peter Rossing


BMC Nephrology. 2010;11 

In This Article


The data introduce urinary proteome analysis as a novel method not only for assessment of new drugs and therapeutic regimens in CKD, but also for the treatment monitoring of patients on renoprotective drugs. Furthermore, the data strengthen the hypothesis that collagens play an important role in the development of diabetic nephropathy (see also[53]) and that collagen turnover may be a highly suitable target for diagnosis and novel therapeutic approaches of this disease.

The proteomic biomarker pattern employed here (the CKD-273 pattern[20]) may well be a superior surrogate in comparison to the frequently used assessment of urinary albumin. To test this hypothesis, UAE and proteomic patterns from samples of longitudinal studies that reach hard endpoints have to be compared.